- PRO 140 single agent therapy is the first successful single agent therapy in the history of HIV for a sub-population of HIV
- Response rate for the company’s innovative PRO 140 nearly doubled after dosage increase
- About 70 percent of phase 3 trial participants treated with higher doses have achieved viral load suppression
- The monotherapy would allow patients to self-administer one dose per week of PRO 140 at home
Biotechnology company CytoDyn Inc. (OTCQB: CYDY) has announced significant developmental progress for its PRO 140 monotherapy for human immunodeficiency virus (HIV) after noticing improved response rates at higher doses of the treatment during phase 3 trials (http://nnw.fm/3g2Np). The company has received clearance from the independent Institutional Review Board (IRB) to increase the weekly dose of PRO 140 from 525 mg to 700 mg, according to a company press release.
The dosage increase will apply to all newly enrolled patients but also to current trial participants who failed to maintain suppressed HIV viral load on a lower dose. Approximately 70 percent of trial participants who started PRO 140 at 525 mg and have been undergoing…
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com